Treatment of patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome: comment on the article by Matsubara et al.
Goldbach-Mansky
Raphaela
R
Pucino
Frank
F
Kastner
Daniel L
DL
D018501:Antirheumatic Agents / Q000627:therapeutic use; D001327:Autoimmune Diseases / Q000188:drug therapy; D002493:Central Nervous System Diseases / Q000188:drug therapy; D000068800:Etanercept; D005334:Fever / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007223:Infant; D007249:Inflammation / Q000188:drug therapy* / Q000378:metabolism; D053590:Interleukin 1 Receptor Antagonist Protein / Q000627:therapeutic use; D053583:Interleukin-1beta / Q000378:metabolism; D015850:Interleukin-6 / Q000378:metabolism; D007592:Joint Diseases / Q000188:drug therapy; D008582:Meningitis, Aseptic / Q000188:drug therapy* / Q000378:metabolism; D010211:Papilledema / Q000188:drug therapy* / Q000378:metabolism; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013577:Syndrome
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D053590:Interleukin 1 Receptor Antagonist Protein; D053583:Interleukin-1beta; D015850:Interleukin-6; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept